Complexities of Next-Generation Sequencing in Solid Tumors: Case Studies.
暂无分享,去创建一个
C. Pritchard | B. Shirts | Heather H. Cheng | E. Yu | E. Konnick | B. Montgomery | Alexandra O. Sokolova | B. Goulart | Ginger J Tsai | Heather H. Cheng | Eric Q. Konnick | Ginger J. Tsai
[1] David R. Jones,et al. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants , 2019, Nature Medicine.
[2] A. Armstrong,et al. Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial. , 2019, Future oncology.
[3] Joon-Oh Park,et al. Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial. , 2019, Journal of Clinical Oncology.
[4] S. Neuhausen,et al. Prevalence and characteristics of likely-somatic variants in cancer susceptibility genes among individuals who had hereditary pan-cancer panel testing. , 2019, Cancer genetics.
[5] S. C. Wang,et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[6] P. Kantoff,et al. Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade , 2019, JAMA oncology.
[7] A. Duval,et al. Association of Primary Resistance to Immune Checkpoint Inhibitors in Metastatic Colorectal Cancer With Misdiagnosis of Microsatellite Instability or Mismatch Repair Deficiency Status , 2019, JAMA oncology.
[8] T. Slavin,et al. The effects of genomic germline variant reclassification on clinical cancer care , 2019, Oncotarget.
[9] M. Ladanyi,et al. Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors , 2018, JAMA oncology.
[10] D. Bowen,et al. Outcomes of 92 patient-driven family studies for reclassification of variants of uncertain significance , 2018, Genetics in Medicine.
[11] Dirk Schadendorf,et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. , 2018, The Lancet. Oncology.
[12] S. Manley,et al. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing , 2018, JAMA.
[13] D. Hayes,et al. Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays , 2018, Clinical Cancer Research.
[14] C. Paweletz,et al. False-Positive Plasma Genotyping Due to Clonal Hematopoiesis , 2018, Clinical Cancer Research.
[15] M. Ladanyi,et al. Therapy-Related Clonal Hematopoiesis in Patients with Non-hematologic Cancers Is Common and Associated with Adverse Clinical Outcomes. , 2017, Cell stem cell.
[16] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[17] Ahmet Zehir,et al. Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. , 2016, The New England journal of medicine.
[18] Ayala Hubert,et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. , 2016, Gynecologic oncology.
[19] D. Stoppa-Lyonnet,et al. Phenotypic cellular characterization of an Ataxia telangiectasia patient carrying a causal homozygous missense mutation , 2003, Human mutation.